CompletedNCT06432322
(GluEsk) Glutamate and Esketamine
Medication studyAges 18–50United KingdomDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- OxfordSee all locations and recruitment
Study information
Study start dateStarted: June 14, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- University of Oxford
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Not clearly listed
- Locations
- United Kingdom
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT06432322
- Official title
Show the full official title
Effects of Esketamine Challenge on Brain Glutamate Release (fMRS), Resting State Connectivity (BOLD-rs-fMRI), and Neuroplasticity (Visual Task)
Get this study by email
Recruitment & locations
CompletedOxford
Questions about this study
Who is behind this study?
The study sponsor is University of Oxford, a university.
Did this study involve medication?
Yes. The study involved medication, including Esketamine nasal spray.
Who was this study for?
Listed age limits: 18 years to 50 years.
Want to explore more studies?
Explore studiesRelated studies
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
A definitive multi-centre pragmatic randomised controlled double-blind trial of the clinical and cost effectiveness of mirtazapine and sertraline versus placebo for the treatment of depression in d...